What are the indications for Avatrombopag/Sukesin?

Avatrombopag is an oral thrombopoietin receptor agonist indicated for the treatment of selected patients who are at risk of bleeding due to thrombocytopenia. Its mechanism of action is to stimulate the proliferation and differentiation of megakaryocytes in the bone marrow by activating the thrombopoietin receptor (TPO-R), thereby increasing the production of platelets. The drug is currently approved for use in two broad groups: patients with chronic liver disease who have thrombocytopenia before elective surgery or invasive diagnostic procedures; and adult patients with chronic immune thrombocytopenia (ITP) who have failed to respond to previous treatments, such as glucocorticoids, immunoglobulins, or splenectomy.

For chronic liver disease-related thrombocytopenia, the therapeutic goal of avatrombopag is not to restore platelets to the normal range, but to increase platelet levels in a short period of time, help patients successfully complete planned surgeries or invasive procedures, and reduce the risk of perioperative bleeding. Thrombocytopenia in such patients is mainly related to factors such as decreased TPO synthesis, splenomegaly, and bone marrow suppression caused by abnormal liver function. Therefore, avatrombopag provides a relatively safe and effective platelet-raising strategy in short-term applications.

In terms of chronic immune thrombocytopenia, avatrombopag is used as a long-term treatment option for patients who have failed first-line treatment and have a protracted disease course. ITP is an autoimmune disease in which the patient's own immune system mistakenly attacks and destroys platelets or inhibits their production, resulting in continued platelet reduction and bleeding symptoms. Avatrombopag has been shown in clinical studies to significantly increase platelet counts, reduce bleeding events and reduce reliance on other immunosuppressive treatments.

It is worth noting that although the drug has a platelet-raising effect, it is not recommended for use in healthy patients with chronic liver disease to artificially raise platelets to normal levels, as this may increase the risk of thrombosis. During use, the dose needs to be dynamically adjusted based on specific platelet counts, and the risk of thrombosis and related side effects must be closely monitored.

Reference materials:https://go.drugbank.com/drugs/DB11995